Trial
NCT01621243
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Momenta Pharmaceuticals, Inc.
Collaborators
—
Condition
Metastatic Pancreatic Cancer
Intervention
nab-paclitaxel
Why stopped
The study was terminated after a pre-planned futility analyses showed an insufficient level of efficacy in the study population to warrant continuation.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-08-29